We currently have 15 products in our development portfolio that represent approximately $15 billion in U.S. brand sales. This portfolio includes both new products, which follow a New Drug Application (NDA) FDA regulatory pathway, and controlled-release generic products, which follow an Abbreviated New Drug Application (ANDA) pathway. Therapeutic areas covered by our portfolio include neurology, cardiovascular, GIT, pain and infection. Several of these products are partnered.